10 results about "Gelsolin" patented technology

The invention belongs to the technical field of antibody preparation, and particularly relates to an antibody for resisting human secretory gelsolin, an antibody pair, a kit and application. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The antibody disclosed by the invention has good specificity and high affinity to human secreted gelsolin, can effectively recognize low-concentration antigens and recognize different antigen epitopes, and provides an ideal antibody tool and a detection system for efficiently, specifically, accurately, sensitively, reliably and stably detecting extremely trace amount of gelsolin.

The present disclosure provides methods, uses, and pharmaceutical compositions with utility in the treatment of acute lung injuries or chronic lung diseases including, bronchopulmonary dysplasia and exacerbations of bronchopulmonary dysplasia.

To provide compositions that can be used to synergistically treat microbial infections.SOLUTION: A composition comprises effective amounts of a gelsolin agent and an antimicrobial agent for treating a microbial infection in a subject, where the composition comprises a clinically acceptable amount of the antimicrobial agent, and where the presence of the gelsolin agent in the composition reduces the minimum effective dose (MED) of the antimicrobial agent in the subject.SELECTED DRAWING: Figure 1A

This invention relates to compositions and methods for treating opioid tolerance in subjects, and to methods for selecting pain relief treatment regimens for subjects suffering from and / or at risk of developing opioid tolerance. Embodiments of the treatment methods of this invention include administering a gelling agent to produce a therapeutic effect against opioid tolerance in the subject.

According to the monoclonal antibody capable of being specifically combined with the gelsolin and the kit containing the monoclonal antibody, the monoclonal antibody is high in affinity, and the kit prepared from the monoclonal antibody is good in precision and can meet the requirement for clinical in-vitro detection of the gelsolin level.

Composition and methods are provided for the treatment of a mammalian subject for axonopathies by increasing activity of axon regeneration-associated gene (RAG) as identified herein, which include without limitation ANXA2, TPA, GSN, VIM, MPP1, ILK, ECM1, CALM1, AND ACAA2. These genes are shown to significantly promote axon regeneration, dramatically protects retinal ganglion cells and optic nerves, and preserve visual function in a clinically relevant model of glaucoma. A therapeutic entity may comprise, for example, a RAG protein, a gene therapy vector comprising a RAG coding sequence, a small molecule that enhances RAG activity, and the like.

The invention discloses application of tin-added ferruginine in clerodendrum trichotomum to preparation of a medicine for reducing blood pressure and protecting blood vessels. The tin-added ferruginine has a good antihypertensive effect and a target organ protection effect on L-NNA induced hypertension rats, has high efficiency and safety, has a multi-target regulation characteristic, is derived from natural products, has relatively low toxic and side effects, and has a unique advantage in treatment of hypertension.

The present invention relates to compositions and methods for treating microbial infections in subjects, in particular methods of administering a gelsolin agent and an antimicrobial agent to produce a synergistic therapeutic effect against a microbial infection in a subject. The present invention also relates to methods for treating viral infections in subjects, including methods that include delayed-dosing methods and / or synergistic methods.

The present invention relates to compositions and methods for treating opioid tolerance in subjects and methods for selecting a pain-reduction therapeutic regimen for a subject who has an opioid tolerance and / or a subject who is at risk of having an opioid tolerance. Embodiments of treatment methods of the invention include administering a gelsolin agent to produce a therapeutic effect against opioid tolerance in a subject.